Complementary and alternative therapies in the treatment of chronic hepatitis C: A systematic review

Journal of Hepatology

Volumn 40, Issue 3, 2004, Pages 491-500

  Coon, Joanna Thompson ^a   Ernst, Edzard ^a  

^a PENINSULA MEDICAL SCHOOL   (United Kingdom)

Author keywords

Complementary medicine; Hepatitis C; Herbal medicine; Systematic review

Indexed keywords

ACETYLCYSTEINE; ADELAVIN; ALPHA INTERFERON; ALPHA TOCOPHEROL; ALPHA2A INTERFERON; ALPHA2B INTERFERON; ALPHAN3 INTERFERON; ANTIOXIDANT; ASCORBIC ACID; BIN GAN LING; BING GAN; CH 100; GLYCYRRHIZIC ACID; HERBACEOUS AGENT; INOSINE; LIVER PROTECTIVE AGENT; NAPROXEN; NEOMINOPHAGEN C; OFLOXACIN; OXYMATRINE; PHLOGENZYM; POLAPREZINC; RIBAVIRIN; SELENIUM; SODIUM SELENITE; THYMOSIN ALPHA1; THYMUS EXTRACT; UNCLASSIFIED DRUG; UNINDEXED DRUG; YI ZHU; ZINC;

ABDOMINAL DISCOMFORT; ALTERNATIVE MEDICINE; ANAPHYLAXIS; ANEMIA; BLEEDING; CHINESE MEDICINE; CLINICAL TRIAL; COPPER DEFICIENCY; DATA BASE; DEPRESSION; DIARRHEA; DRUG EFFECT; DRUG OVERDOSE; DRUG RESEARCH; DRUG SAFETY; ERYTHEMA MULTIFORME; EYE FUNDUS; FATIGUE; FLU LIKE SYNDROME; GLYCYRRHIZA GLABRA; HAIR LOSS; HEADACHE; HEART PALPITATION; HEMATOLOGIC DISEASE; HEPATITIS C; HUMAN; HYPERTENSION; HYPOKALEMIA; INJECTION PAIN; INJECTION SITE; INSOMNIA; INTERSTITIAL PNEUMONIA; MENTAL INSTABILITY; NAIL DISEASE; NAUSEA; NERVOUSNESS; ONYCHOLYSIS; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SODIUM RETENTION; SYNCOPE; THROMBOCYTOPENIA; TRADITIONAL MEDICINE; TREATMENT OUTCOME; VOMITING; WEIGHT GAIN;

EID: 1242314799     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2003.11.014     Document Type: Article

References (53)

1. Report of a WHO consultation in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. Global surveillance and control of hepatitis C. J Viral Hepat. 6:1999;35-47.
2. Hepatitis C strategy for England. August 2002.
3. Chander G., Sulkowski M.S., Jenckes M.W., Torbenson M.S., Herlong H.F., Bass E.B., Gebo K.A. Treatment of chronic hepatitis C: a systematic review. Hepatology. 36:2002;S135-S144.
4. Baker D.E. Pegylated interferon plus ribavirin for the treatment of chronic hepatitis C. Rev Gastroenterol Disord. 3:2003;93-109.
5. Liang T.J., Rehermann B., Seeff L.B., Hoofnagle J.H. Pathogenesis, natural history, treatment and prevention of hepatitis C. Ann Intern Med. 132:2000;296-305.
6. Falck-Ytter Y., Kale H., Mullen K.D., Sarbah S.A., Sorescu L., McCullough A.J. Surprisingly small effect of antiviral treatment in patients with hepatitis C. Ann Intern Med. 136:2002;288-292.
7. Seeff L.B., Lindsay K.L., Bacon B.R., Kresina T.F., Hoofnagle J.H. Complementary and alternative medicine in chronic liver disease. Hepatology. 34:2001;596-603.
8. Jadad A.R., Moore A., Carroll D., Jenkinson C., Reynolds D.J., Gavaghan D.J., McQuay H.J. Assessing the quality of reports of randomised clinical trials: is blinding necessary? Control Clin Trials. 17:1996;1-12.
9. Look M.P., Gerard A., Rao G.S., Sudhop T., Fischer H.-P., Sauerbruch T., Spengler U. Interferon/antioxidant combination therapy for chronic hepatitis C - a controlled pilot trial. Antiviral Res. 43:1999;113-122.
10. Neri S., Ierna D., Antoci S., Campanile E., D'Amico R.A., Noto R. Association of alpha-interferon and acetyl cysteine in patients with chronic C hepatitis. Panminerva Med. 42:2000;187-192.
11. Andreana A., Zampino R., Tonziello A., Adinolfi L.E., Utili R., Ruggiero G. Treatment with N-acetyl cysteine (NAC) or ofloxacin (OFLO) as adjunct to IFN failed to achieve response in chronic hepatitis C patients non-responding to IFN alone: a phase II study. Hepatology. 26:1997;218A.
12. Grant P.R., Black A., Garcia N., Prieto J., Garson J.A. Combination therapy with interferon-alpha plus N-acetyl cysteine for chronic hepatitis C: a placebo controlled double blind multicentre study. J Med Virol. 61:2000;439-442.
13. Bernhard M.C., Junker E., Hettinger A., Lauterburg B.H. Time course of total cysteine, glutathione and homocysteine in patients with chronic hepatitis C treated with interferon-alpha with and without supplementation with N-acetylcysteine. J Hepatol. 28:1998;751-755.
14. Ideo G., Bellobuono A., Tempini S., Mondazzi L., Airoldi A., Benetti G., et al. Antioxidant drugs combined with alpha-interferon in chronic hepatitis C not responsive to alpha-interferon alone: a randomised, multicentre study. Eur J Gastroenterol Hepatol. 11:1999;1203-1207.
15. von Herbay A., Stahl W., Niederau C., Sies H. Vitamin E improves the aminotransferase status of patients suffering from viral hepatitis C: a randomised, double blind, placebo-controlled study. Free Radic Res. 27:1997;599-605.
16. Kelly G.S. Clinical applications of N-acetyl cysteine. Altern Med Rev. 3:1998;114-127.
17. Jones A.L., Jarvie D.R., Simpson D., Hayes P.C., Prescott L.F. Pharmacokinetics of N-acetyl cysteine are altered in patients with chronic liver disease. Aliment Pharmacol Ther. 11:1997;787-791.
18. Murray M.T. Selenium. Encyclopedia of nutritional supplements. 1996;222-228 Prima, Rocklin, CA.
19. Selenium intoxication - New York. J Am Med Assoc. 251:1984;1938.
20. Sherman K.E., Sjogren M., Creager R.L., Damiano M.A., Fremman S., Lewey S., et al. Combination therapy with thymosin alpha 1 and interferon for the treatment of chronic hepatitis C infection: a randomised, placebo-controlled double blind trial. Hepatology. 27:1998;1128-1135.
21. Moscarella S., Buzzelli G., Romanelli R.G., Monti M., Giannini C., Careccia G., et al. Interferon and thymosin combination therapy in naive patients with chronic hepatitis C: preliminary results. Liver. 18:1998;366-369.
22. Sherman K.E., Sjogren M., Creager R.L., Freeman S., O'Brian J., Root S., Davis D. Hepatitis C RNA response to combined therapy with thymosin alpha-1 and interferon. Hepatology. 20:1994;207A.
23. Andreone P., Cursaro C., Gramenzi A., Buzzi A., Covarelli M.G., Di Giammarino L., et al. A double blind, placebo controlled, pilot trial of thymosin alpha 1 for the treatment of chronic hepatitis C. Liver. 16:1996;207-210.
24. Raymond R.S., Fallon M.B., Abrams G.A. Oral thymic extract for chronic hepatitis C in patients previously treated with interferon. A randomised, double blind, placebo controlled trial. Ann Intern Med. 129:1998;797-800.
25. Takagi H., Nagamine T., Abe T., Takayama H., Sato K., Otsuka T., et al. Zinc supplementation enhances the response to interferon therapy in patients with chronic hepatitis C. J Viral Hepat. 8:2001;367-371.
26. Murray M.T. Zinc. Encyclopedia of nutritional supplements. 1996;181-189 Prima, Rocklin, CA.
27. Fujisawa K., Suzuki H., Yamamoto S., et al. Therapeutic effects of liver hydrolysate preparations on chronic hepatitis-A double blind, controlled study. Asian Med J. 26:1983;497-526.
28. Stauder G., Kabil S. Oral enzyme therapy in hepatitis C patients. Int J Immunother. 13:1997;153-158.
29. Han G.P., Wang Z.Y., Peng S.L. Binggan capsule combined with interferon for treatment of 30 cases of hepatitis C. Henan J Tradit Chin Med. 12:1997;43-44.
30. Pei Z.G., Liu Y.L., Zhao S.M. Therapeutic observation of Binggan decoction combined with interferon in 46 cases of hepatitis C. Pract J Integrating Chin Mod Med. 9:1996;444.
31. Batey R.G., Bensoussan A., Fan Y.Y., Bollipo S., Hossain M.A. Preliminary report of a randomised, double blind placebo controlled trial of a Chinese herbal medicine preparation CH100 in the treatment of chronic hepatitis C. J Gastroenterol Hepatol. 13:1998;244-247.
32. Chen J., Han X.Y., Miao Y.X., Zhang S.X., Fu S.X., Liu Z.M., et al. Clinical study of Bingganling for treatment of hepatitis C. Hebei J Tradit Chin Med. 20:1998;137-138.
33. Jiang Y.H. Treatment of 20 cases of hepatitis C using a self-prescribed Yizhu oral liquid. J Nanjing Univ Tradit Chin Med. 15:1999;256.
34. Xiao H.Q., Luo R.Y., Wu W.F., Deng T.T. Effect of Gansu capsule on chronic hepatitis C. J Guangzhou Univ Tradit Chin Med. 16:1999;24-27.
35. Yu W.J. Yi Er Gan decoction for treatment of 40 cases of hepatitis C. New J Tradit Chin Med. 27:1995;47.
36. Bahrke M.S., Morgan W.P. Evaluation of the erogenic properties of ginseng. Sports Med. 29:2000;113-133.
37. Vogler B.K., Pittler M.H., Ernst E. The efficacy of ginseng. A systematic review of randomised clinical trials. Eur J Clin Pharmacol. 55:1999;567-575.
38. Fujiyama S., Chikazawa H., Honda Y., Kukida T., Iida S., Kawakami T., et al. Treatment of chronic active hepatitis C with interferon alpha 2b-alone and in combination with Stronger Neo Minophagen C. Biother Jpn. 12:1998;1495-1513.
39. Suzuki Y., Ikeda K., Saitoh S., Kobayashi M., Tsubota A., Koida I., et al. A prospective randomised administration of Stronger Neo Minophagen C as an adjuvant therapy for chronic hepatitis type C treated with interferon. Acta Hepatol Jpn. 37:1996;363-367.
40. van Rossum T.G.J., Vulto A.G., Hop W.C., Brouwer J.T., Niesters H.G., Schalm S.W. Intravenous glycyrrhizin for the treatment of chronic hepatitis C: a double blind, randomised, placebo controlled phase I/II trial. J Gastroenterol Hepatol. 14:1999;1093-1099.
41. Tsubota A., Kumada H., Arase Y., Chayama K., Saitoh S., Ikeda K., et al. Combined ursodeoxycholic acid and glycyrrhizin therapy for chronic hepatitis C virus infection: a randomized controlled trial in 170 patients. Eur J Gastroenterol Hepatol. 11:1999;1077-1083.
42. Conn J.W., Rovner D.R., Cohen E.L. Licorice-induced pseudoaldosteronism. J Am Med Assoc. 205:1968;492-496.
43. Li J., Li C., Zeng M. Preliminary study on therapeutic effect of oxymatrine in treating patients with chronic hepatitis C. Zhongguo Zhng Xi Yi Jie He Za Zhi. 48:1998;227-229.
44. Marcellin P., Boyer N., Gervais A., Martinot M., Pouteau M., Castelnau C., et al. Long term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon alpha therapy. Ann Intern Med. 127:1997;875-881.
45. Poynard T., McHutchison J., Davis G.L., Esteban-Mur R., Goodman Z., Bedossa P., et al. Impact of interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C. Hepatology. 32:2000;1131-1137.
46. Di Bisceglie A.M., Hoofnagle J.H. Optimal therapy of hepatitis C. Hepatology. 36:2002;S121-S127.
47. Lindsay K.L. Introduction to therapy of hepatitis C. Hepatology. 36:2002;S114-S120.
48. Easterbrook P.J., Berlin J.A., Gopalan R., Matthews D.R. Publication bias in clinical research. Lancet. 337:1991;867-872.
49. Schmidt K., Pittler M.H., Ernst E. Bias in alternative medicine is still rife but is diminishing. Br Med J. 323:2001;1071.
50. McCulloch M., Broffman M., Gao J., Colford J.M. Chinese herbal medicine and interferon in the treatment of chronic hepatitis B: a meta-analysis of randomised, controlled trials. Am J Public Health. 92:2002;1619-1627.
51. Tang J.-L., Zhan S.-Y., Ernst E. Review of randomised controlled trials of traditional Chinese medicine. Br Med J. 319:1999;160-161.
52. Peyton B.G., Spears T.L., Lindsey A., Lindsey J., Sharma V.K., Raufmann J.-P. A survey of use of herbal medicine in patients with hepatitis C. Hepatology. 30:1999;191A.
53. Sato A., Mizuno H., Tominaga T., Suga M., Suemori S., Suzuki H., Suzuki M. Efficacy of combination therapy with interferon and adelavin in patients of chronic hepatitis C with hepatitis C in viral (HCV) genotype 1b. Ther Res. 19:1998;295-298.